Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Metabolic Classification of Thyroid Nodules Uses MS Imaging

By LabMedica International staff writers
Posted on 26 Oct 2019
Fine-needle aspiration (FNA) biopsy is a well-established technique for diagnosis of suspicious thyroid lesions. More...
However, histologic discrimination between malignant and benign thyroid nodules from FNA can be challenging.

Each year, thanks to inconclusive tests for thyroid cancer, thousands of people undergo unnecessary surgeries to remove part or all of their thyroids. A new test based on the unique chemical fingerprints of thyroid cancer might change that and it is faster and about two-thirds more accurate than the diagnostic tests doctors use today.

Biochemists at the University of Texas at Austin (Austin, TX, USA) and their colleagues used a technology called mass spectrometry imaging. The new metabolic thyroid test identifies metabolites produced by cancerous cells that act as a kind of diagnostic fingerprint. The team worked on identifying these diagnostic metabolic fingerprints for over two years using 178 patient tissues before starting a pilot clinical study. During the clinical study, 68 new patients were tested, nearly a third of who had received inconclusive FNA results. The new metabolic thyroid test returned a false positive only about 1 time in 10 and could have prevented 17 patients in the study from undergoing unnecessary surgeries.

The scientists employed desorption electrospray ionization mass spectrometry (DESI-MS) imaging to diagnose thyroid lesions based on the molecular profiles obtained from FNA biopsy samples. Based on the molecular profiles obtained from malignant thyroid carcinomas and benign thyroid tissues, classification models were generated and used to predict on DESI-MSI data from FNA material with high performance. Their results demonstrate the potential for DESI-MSI to reduce the number of unnecessary diagnostic thyroid surgeries.

James W. Suliburk, MD, FACS, a co-principal investigator and head of endocrine surgery at Baylor College of Medicine (Houston, TX, USA) said, “With this next generation test, we can provide thyroid cancer diagnoses faster and with more precision than current techniques, this will be the new state-of-the-art. We are able to do this analysis directly on the FNA sample and much more rapidly than the current process, which could take between three and 30 days.” The study was published on October 7, 2019, in the journal Proceedings of the National Academy of Sciences.

Related Links:
University of Texas at Austin
Baylor College of Medicine


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.